Assessing the correlation between health-related quality of life in acromegaly patients and biochemical and clinical characteristics of their condition
DOI:
https://doi.org/10.6016/ZdravVestn.3500Keywords:
acromegaly, disease control, SAGIT score, AcroQoL Questionnaire, health related quality of lifeAbstract
Background: The gap between the treatment goals for acromegaly as defined by clinicians and patients has contributed to developing new tools for a standardized assessment of disease control status. Through our research, we aimed to evaluate the clinical utility of two new comprehensive assessment tools for acromegaly: the SAGIT Instrument and the AcroQoL questionnaire. Additionally, we examined the correlation between the subscores, the overall score, and traditional treatment goals.
Methods: The cross-sectional study included 72 patients diagnosed and treated between 2000 and 2020. The SAGIT score at diagnosis before treatment was determined retrospectively. During follow-up, we determined the SAGIT score again and invited patients to complete the AcroQoL questionnaire.
Results: All SAGIT subscores decreased significantly from diagnosis to the last examination. SAGIT at baseline did not discriminate against the current disease control status. However, higher global score and a subscore »T« at diagnosis were associated with uncontrolled disease after the first-line treatment. The total SAGIT score at the follow-up and its subscores »G« and »I« were able to discriminate between patients with cured/pharmacologically controlled and untreated disease. At follow-up, the AcroQoL score was 69.3, with the highest score in the »Personal relations subscale« and the most affected »Physical scale«. Both at diagnosis and follow-up, there were significant negative correlations between »S« and »A« subscores of the SAGIT score and AcroQoL. Higher BMI, presence of soft tissue swelling, joint symptoms, headaches, sleep apnea, and hypertension were associated with impaired quality of life of our patients.
Conclusion: We confirmed the complementary role of the SAGIT score and the AcroQoL questionnaire and identified new potential treatment targets that could improve the quality of life of acromegaly patients.
Downloads
References
1. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, et al.; Mexican Acromegaly Registry Group. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997-4004.
DOI: 10.1210/jc.2016-1937
PMID: 27428551
2. Otto G, Acromegaly ML. Acromegaly. Nat Rev Dis Primers. 2019;5(1):21.
DOI: 10.1038/s41572-019-0076-1
PMID: 30899021
3. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4-9.
DOI: 10.1007/s11102-016-0754-x
PMID: 27743174
4. Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA. Acromegaly: clinical features at diagnosis. Pituitary. 2017;20(1):22-32.
DOI: 10.1007/s11102-016-0772-8
PMID: 27812777
5. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-202.
DOI: 10.1172/JCI39375
PMID: 19884662
6. Sardella C, Lombardi M, Rossi G, Cosci C, Brogioni S, Scattina I, et al. Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest. 2010;33(1):20-5.
DOI: 10.1007/BF03346555
PMID: 20203538
7. Badia X, Trainer P, Biermasz NR, Tiemensma J, Carreño A, Roset M, et al. Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. J Med Econ. 2018;21(4):382-9.
DOI: 10.1080/13696998.2017.1419960
PMID: 29261359
8. Akirov A, Masri-Iraqi H, Dotan I, Shimon I. The Biochemical Diagnosis of Acromegaly. J Clin Med. 2021;10(5):1147.
DOI: 10.3390/jcm10051147
PMID: 33803429
9. Crespo I, Valassi E, Webb SM. Update on quality of life in patients with acromegaly. Pituitary. 2017;20(1):185-8.
DOI: 10.1007/s11102-016-0761-y
PMID: 27730455
10. Giustina A, Mazziotti G, Giubbini R. Molecular imaging in acromegaly: should clinicians look carefully at developments in the field? Nucl Med Commun. 2014;35(9):897-9.
DOI: 10.1097/MNM.0000000000000155
PMID: 24942477
11. Freda PU. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxford). 2009;71(2):166-70.
DOI: 10.1111/j.1365-2265.2009.03556.x
PMID: 19226264
12. Arshad MF, Ogunleye O, Ross R, Debono M. Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study). Pituitary. 2021;24(5):768-77.
DOI: 10.1007/s11102-021-01153-4
PMID: 33982222
13. Christofides EA. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence. 2016;10:1217-25.
DOI: 10.2147/PPA.S102302
PMID: 27471378
14. Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, et al.; SAGIT Investigator Group. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary. 2016;19(1):39-49.
DOI: 10.1007/s11102-015-0681-2
PMID: 26377024
15. Gatto F, Campana C, Cocchiara F, Corica G, Albertelli M, Boschetti M, et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. 2019;20(3):365-81.
DOI: 10.1007/s11154-019-09506-y
PMID: 31342434
16. Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, et al. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary. 2019;22(5):476-87.
DOI: 10.1007/s11102-019-00977-5
PMID: 31338660
17. van der Meulen M, Zamanipoor Najafabadi AH, Broersen LH, Schoones JW, Pereira AM, van Furth WR, et al. State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;107(5):1225-238.
DOI: 10.1210/clinem/dgab874
PMID: 34871425
18. Webb SM, Badia X, Surinach NL, Astorga R, Benito P, Catalá M, et al.; Spanish AcroQol Study Group. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol. 2006;155(2):269-77.
DOI: 10.1530/eje.1.02214
PMID: 16868140
19. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab. 2005;90(6):3337-41.
DOI: 10.1210/jc.2004-1565
PMID: 15755865
20. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf). 2005;63(1):103-10.
DOI: 10.1111/j.1365-2265.2005.02307.x
PMID: 15963069
21. Maione L, Chanson P. National acromegaly registries. Best Pract Res Clin Endocrinol Metab. 2019;33(2).
DOI: 10.1016/j.beem.2019.02.001
PMID: 30894298
22. Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182(6):523-31.
DOI: 10.1530/EJE-20-0019
PMID: 32213651
23. Starnoni D, Daniel RT, Marino L, Pitteloud N, Levivier M, Messerer M. Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. Acta Neurochir (Wien). 2016;158(11):2109-21.
DOI: 10.1007/s00701-016-2903-4
PMID: 27586125
24. Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, et al. International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. J Clin Endocrinol Metab. 2021;106(12):3555-68.
DOI: 10.1210/clinem/dgab536
PMID: 34313752
25. Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxford). 2007;67(3):358-62.
DOI: 10.1111/j.1365-2265.2007.02891.x
PMID: 17555502
26. Mangupli R, Camperos P, Webb SM. Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary. 2014;17(6):495-9.
DOI: 10.1007/s11102-013-0533-x
PMID: 24178448
27. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab. 2004;89(11):5369-76.
DOI: 10.1210/jc.2004-0669
PMID: 15531483
28. T’Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R. Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol. 2007;157(4):411-7.
DOI: 10.1530/EJE-07-0356
PMID: 17893254
29. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol. 2006;155(6):831-7.
DOI: 10.1530/eje.1.02292
PMID: 17132752
30. Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, Sievers C, et al. Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol (Lausanne). 2017;8(MAR):40.
DOI: 10.3389/fendo.2017.00040
PMID: 28316591
31. O’Dwyer MC, Meixner K, Albiac LC, El Khoury C, Capizzano JN, Ramakrishnan M, et al. Health-Related Quality of Life for People With Acute and Chronic Illnesses During the COVID-19 Pandemic. J Am Board Fam Med. 2021;34(3):509-21.
DOI: 10.3122/jabfm.2021.03.200593
PMID: 34088811
32. Pivonello R, Neggers S, Imran SA. Psychopathology in Acromegaly - Real and Perceived. J Clin Endocrinol Metab. 2023;108(10):2470-4.
DOI: 10.1210/clinem/dgad237
PMID: 37139644
33. Pantanetti P, Sonino N, Arnaldi G, Boscaro M. Self image and quality of life in acromegaly. Pituitary. 2002;5(1):17-9.
DOI: 10.1023/A:1022145116901
PMID: 12638721
34. Roerink SH, Wagenmakers MA, Wessels JF, Sterenborg RB, Smit JW, Hermus AR, et al. Persistent self-consciousness about facial appearance, measured with the Derriford appearance scale 59, in patients after long-term biochemical remission of acromegaly. Pituitary. 2015;18(3):366-75.
DOI: 10.1007/s11102-014-0583-8
PMID: 24965695
35. Gu J, Xiang S, He M, Wang M, Gu Y, Li L, et al. Quality of Life in Patients with Acromegaly before and after Transsphenoidal Surgical Resection. Int J Endocrinol. 2020;2020.
DOI: 10.1155/2020/5363849
PMID: 32831834
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Slovenian Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
